Ramucirumab

證據等級: L5

預測適應症: 10 個

Ramucirumab: From Advanced Solid Tumours to Uterine Ligament Adenocarcinoma

One-Sentence Summary

Ramucirumab is an anti-VEGFR2 monoclonal antibody whose antitumour effect through blockade of tumour angiogenesis is established in gastric cancer, NSCLC, hepatocellular carcinoma and colorectal cancer (per the mechanistic rationale in this evidence pack; not independently confirmed via structured indication data in this pack). The TxGNN model predicts it may be effective for uterine ligament adenocarcinoma, but currently 0 clinical trials and 0 publications support this specific direction — this is a model-prediction-only signal.

Quick Overview

Item	Content
Original Indication	Not confirmed in this evidence pack (structured field empty); mechanistic rationale references established use in gastric cancer, NSCLC, hepatocellular carcinoma and colorectal cancer
Predicted New Indication	Uterine ligament adenocarcinoma
TxGNN Prediction Score	99.95%
Evidence Level	L5
Denmark Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

The original_moa field for Ramucirumab is not populated in this evidence pack (flagged as a High-severity data gap, DG002 — pending DrugBank API lookup). However, the repurposing rationale attached to the top prediction describes Ramucirumab as an anti-VEGFR2 monoclonal antibody that inhibits tumour angiogenesis, a mechanism already validated across multiple solid tumours including gastric cancer, NSCLC, hepatocellular carcinoma and colorectal cancer.

Uterine ligament adenocarcinoma is a rare gynaecological malignancy. The mechanistic link proposed here is a broad extrapolation from anti-angiogenic activity in other solid tumours, rather than a disease-specific finding — the evidence pack explicitly notes there is no direct data on VEGFR2 expression or angiogenesis-dependence in this specific tumour type, so the connection “cannot be established as a specific link” beyond general class-level plausibility.

Because there are no clinical trials or publications testing Ramucirumab in this indication, the mechanistic argument currently stands alone as the entire evidentiary basis for the prediction.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Denmark Market Information

Ramucirumab currently has no marketing authorisations on record in this evidence pack (total_licenses: 0, market_status: 未上市 / Not marketed). No licence table can be produced.

Cytotoxicity

Ramucirumab is an antineoplastic monoclonal antibody (anti-VEGFR2, anti-angiogenic class), so this section applies.

Item	Content
Cytotoxicity Classification	Targeted therapy (anti-VEGFR2 monoclonal antibody, antiangiogenic)
Myelosuppression Risk	Please refer to the Summary of Product Characteristics (SmPC) warnings and precautions
Emetogenicity Classification	Please refer to the Summary of Product Characteristics (SmPC) warnings and precautions
Monitoring Items	Please refer to the Summary of Product Characteristics (SmPC) warnings and precautions
Handling Protection	Please refer to the Summary of Product Characteristics (SmPC) warnings and precautions

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information. Note: the evidence pack flags a Blocking-severity data gap (DG001) — TFDA/SmPC-level warnings and contraindications are not yet available, which by itself prevents this candidate from entering the S1 safety pre-assessment stage.

Conclusion and Next Steps

Decision: Hold

Rationale:

Evidence level is L5 (model prediction only) — there are zero clinical trials and zero publications supporting Ramucirumab in uterine ligament adenocarcinoma, and the mechanistic link is a generic class-level extrapolation rather than a disease-specific finding. Combined with a Blocking-severity safety data gap, the candidate cannot proceed further at this time.

To proceed, the following is needed:

TFDA/SmPC-sourced warnings and contraindications (DG001, Blocking) — required before any S1 safety pre-assessment
Confirmed mechanism of action from DrugBank (DG002)
Disease-specific supporting evidence (preclinical, case reports, or trials) for VEGFR2/angiogenesis relevance in uterine ligament adenocarcinoma specifically, given its rarity and the lack of any registered studies
Clarification of Ramucirumab’s confirmed original indication(s), since the structured original_indications field in this pack is currently empty
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.